Serologic Indicators of HBV, HCV and HIV in Hemodialysis Patients in Van Training and Research Hospital

Objectives: It was aimed to examine the blood-borne infections in patients to whom hemodialysis is applied due to chronic renal failure and evaluating the effectiveness of infection control programs in this study. Materials and methods: Patients who underwent routine hemodialysis between January and August 2018 were included into the study. The study was designed as a retrospective. The blood samples taken from patients during their health screenings were tested with the macro ELISA method for HBsAg, Anti-HBs, Anti-HCV and Anti-HIV observations at the microbiology laboratory and the clinical information was acquired from patient files. Results: There were no patients who developed reactivity of chronic HBsAg and anti-HIV based on dialysis. One of eight Anti-HCV reactive patients was not included in the analyses since the patient had the disease before undergoing dialysis. It was detected that Anti-HCV reactive patients underwent dialysis for more than five years and they had a lower mean age (p<0,005). In only five (55.5%) of nine patients who received hepatitis B vaccine, protective antibody titer was reached. Conclusion: Appropriate infection control measures, immunizations and education of patients and health workers come to the forefront in reducing the frequency of blood-borne infections in hemodialysis patients